Further preclinical research activities are being conducted using TH1904, our second investigational PDC (doxorubicin conjugate). In vitro and in vivo experiments using TH1904 have demonstrated results similar to those obtained with TH1902 and support the development of additional investigational compounds using our SORT1+ TechnologyTM that may help in the fight against cancer.

In vivo pre-clinical studies have shown that TH1904 was better tolerated than free doxorubicin and caused more potent inhibition of human ovarian tumor xenografts grown in mice. These results strongly support the future clinical use of this platform to generate novel personalized therapeutics for specific targeting of sortilin-positive tumors.